CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Five years ago this month, in November 2020, medical history was made at Richmond Pharmacology when a patient received the ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

From custom gene editing to a discovery that could help stop pancreatic cancer before it starts, these advances offer a ...

All the way back in 49 BCE, emperor of the known world Julius Caesar sported history’s first known combover — which tells you ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

Dr Sydney Calkin, from the Department of Geography in Queen Mary University of London’s School of Society and Environment, ...

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...